Welcome to our dedicated page for ARROWHEAD PHARMACEUTICALS SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARROWHEAD PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARROWHEAD PHARMACEUTICALS's regulatory disclosures and financial reporting.
State Street Corporation filed a Schedule 13G reporting beneficial ownership of 6,371,056 shares of Arrowhead Pharmaceuticals Inc. common stock, representing 4.6% of the class as of the event date 06/30/2025. The filing is signed on behalf of State Street by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer, on 08/08/2025.
The statement shows no sole voting or dispositive power (0 shares) and records shared voting power of 5,952,902 shares and shared dispositive power of 6,371,056 shares. Item 7 identifies State Street advisory and funds entities as affiliated managers (for example, SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited). The filing does not indicate a group filing or identify any other person with >5% ownership.